Patient Derived Xenografts Market– Industry

Definition: Global Patient Derived Xenografts

Patient derived xenograft (PDX) is a process of implanting patient’s tumor tissues into experimental mice model. Various types of patient-derived orthotropic xenograft models are available for cancers like chronic lymphocytic leukemia, pancreatic cancer, gastric cancer, colorectal cancer, intrahepatic cholangiocarcinoma.
PDX models help in the assessment of human cancer biology, identification of therapeutic drugs, preclinical screening, and evaluation of drugs.
PDX models are valuable tools for evaluation of chemical entity, monoclonal antibody, anti-cancer microorganisms and drug combination in-vivo.
Chimeric antigen receptors (CAR) Tcells have receptors (CAR) Tcells have a promising treatment for B cell leukemia. PDX are frequently used for CART-cell therapy.
This market report defines the market trends and forecast the upcoming opportunities and threats of the patient derived xenograft market in the next 8 years.

Analysis: Global Patient Derived Xenografts

The Global Patient Derived Xenografts Market is expected to reach USD 263.98 Million by 2025, from USD 77.8 Million in 2017 growing at a CAGR of 16.5% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2017, the base year of calculation is 2017 and the forecast period is 2018 to 2025.
Major Market Drivers and Restraints:
  • Increased research and development in pharmaceutical and biotechnology company
  • Government support in pharmaceutical and biotechnology industry
  • Increased in the number of cancer patients
  • Inflation in demand of personalized medicines
  • Advancement in technology for developing better applications.
  • Downward pricing pressure owing to its commodity nature

Market Segmentation:

  • The global patient derived xenografts market is segmented on basis of type, tumor type, application, end users and geography.
  • Based on type, the global patient derived xenografts market is segmented into mice models and rat models
  • Based on the tumor type, the global patient derived xenografts market is segmented into hematological tumor models, urological tumor models, respiratory tumor models, gynecological tumor models, gastrointestinal tumor models and other tumor models.

Competitive Analysis: Global Patient Derived Xenografts Market

The global patient derived xenograft market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of patient derived xenograft market for global, Europe, North America, Asia Pacific and South America.

Major Market competitors/players: Global Patient Derived Xenografts Market

Some of the major players operating in the global patient derived xenografts market are:-
Bioduro, Champion Oncology, Inc, Charles River, Crown Bioscience Inc, EPO Berlin-Buch GmbH, Hera BioLabs, Horizon Discovery Group plc, Oncodesign, Pharmatest Services, Shanghai LIDE, The Jackson Laboratory, Urolead, WuXi AppTec, Xenopat, xentech, among others.
CONTACT US:
USA Number – +1 888 387 2818 (Toll – Free)
Email : sopan.gedam@ databridgemarketresearch.com

Comments

Popular posts from this blog

Micro-Location Technology Market – Industry Trends

Global Dairy Alternative Market – Industry Trends and Forecast to 2026

Medical Waste Management Market Forecast to 2025